SecBot SecBot
Insider Cluster (3 insiders) ·Filed Jul 2, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $6.0M total
Actionable Insight • Neutral

The selling is too small to be informative. Monitor for any larger insider activity or a follow-up 8-K with material corporate news. For now, this cluster has no actionable trade signal.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$57.77
T+0 close · Jul 2, 2026 · via day close
Latest settled
+1.04%
T+60 · $58.37
Vs SPY
−2.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $57.77entry
  2. T+1 · 4mo ago −1.47%α −2.34% · $56.92
  3. T+5 · 4mo ago +0.33%α −0.60% · $57.96
  4. T+20 · 4mo ago +2.16%α +2.58% · $59.02
  5. T+60 · 7w ago +1.04%α −2.53% · $58.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two EVP-level insiders at Royalty Pharma (RPRX) sold a combined $7.85M in shares over a 7-day window, but this represents only ~0.024% of the company's $32.1B market cap. The selling is trivial in size relative to the company's valuation and is unlikely to carry a material signal.

Key Financial Metrics

Direction
selling
Total Value
$7.9M
Insiders
3

Key Facts

  • EVP & Chairman, Partnering Christopher Hite sold $7.35M across four open-market trades at $56.44–$57.10.
  • EVP, Research & Investments Marshall Urist sold $508K at $55.88.
  • Director Bonnie Bassler received a non-cash grant of 689 shares worth $37.5K.
  • Total insider cash sales of $7.85M are just 0.024% of RPRX's $32.1B market cap.
  • No 10b5-1 plan indication; the sales may be routine diversification.

Financial Impact

Insider sales of $7.85M are negligible relative to a $32.1B market cap (0.024%). No material financial impact.

Risk Factors

  • Insider sales could accelerate if the stock appreciates further, but current levels are not alarming.
  • No correlation with upcoming earnings or corporate events based on available data.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RPRX-1783062576498

Track record

23 reports on RPRX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $69.31 +2.58% ▲ +2.07% −1.22% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  4. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $69.31 +2.59% ▲ +3.63% +4.54% vs SPY
  5. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $69.31 −20.27% ▲ +2.46% +3.77% vs SPY
  6. Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $69.31 −14.39% ▲ +3.50% +2.38% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $69.31 +14.44% ▲ +2.24% +1.12% vs SPY
  8. Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $69.31 +18.36% ▲ +3.45% +5.41% vs SPY
  9. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $69.31 +20.02% ▲ +2.55% +2.19% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Viewing Entry $57.77 to $57.96 Now $69.31 +19.98% ▲ +0.33% −0.60% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (12h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026